ArticleFrontiers in oncology2022

Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer.

Jun Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.